Drug
Thrombolytic
Thrombolytic is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(1)
Other(1)
Detailed Status
Withdrawn1
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 41 (50.0%)
N/A1 (50.0%)
Trials by Status
withdrawn133%
recruiting133%
unknown133%
Recent Activity
1 active trials
Showing 3 of 3
withdrawn
The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI
NCT03267199
recruitingphase_4
Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism
NCT05493163
unknownnot_applicable
Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.
NCT05354128
Clinical Trials (3)
Showing 3 of 3 trials
NCT03267199
The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI
NCT05493163Phase 4
Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism
NCT05354128Not Applicable
Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3